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Fold inhibition of infection Table S2 . Neutralization of R5-SHIVs by reference plasmas, sCD4 and broadly neutralizing antibodies (TZM-bl system).
(Related to Experimental Procedures)
Neutralization sensitivity of R5-SHIVs given as reciprocal dilution for reference plasmas and sCD4 or antibody concentration (µg/ml) at which 50% reduction of virus infectivity was achieved. Viral RNA copies/ml in plasma and serum obtained from animals infused with control (for comparison) or PGT121 antibodies. Samples were obtained from both groups of animals at the time of the 'blips' in PGT121 infused animals, 4 weeks post-inoculation for animals 1,2 and 3 and 3 weeks post-inoculation for animals 4, 5 and 6. 30 RNA copies/ml is the limit of detection for this assay.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Cloning strategy
HIV-1 Env-coding sequences were amplified using degenerate PCR primers that To determine the statistical significance of the outcome from animals infected with group 1 viruses the χ 2 test was used.
The 'winner' Env sequences were derived from samples obtained from (i) subject 1054, a male subject from South Carolina with unknown risk factors, plasma VL 320,000 RNA copies/ml at estimated 2-3 weeks post-infection, and (ii) subject AD081, a male subject from New York, with a history of intramuscular steroid use with shared needles, plasma VL 136,000 RNA copies/ml at estimated 6 weeks post-infection.
Flow cytometry
Absolute cell counts were performed on EDTA-anti-coagulated whole blood described (Del Prete et al., 2012; Hatziioannou et al., 2009; Tabb et al., 2013) APC-Cy7 (SP34-2), and Ki67 FITC (B56).
